Lifetime Achievement Award for MELGEN Principal Coordinator at SMR Congress 2017

It has been an excellent Society for Melanoma Research (SMR) Congress for MELGEN this year. The 14th International Congress of the Society for Melanoma Research which this year was a joint meeting with the 9th World Congress of Melanoma was held in Brisbane, Australia, from 18th to the 21st October, 2017. Attracting researchers and clinicians from around the globe to share the latest discoveries in the field of melanoma research, this prestigious meeting covers a diverse range of melanoma research including prevention, clinical diagnosis, genetics and basic cell science, treatment and patient support.

MELGEN Award Winners at the 14th International Congress Of the Society for Melanoma Research, Brisbane, Australia, 18th-21st October 2017. Bottom Right: Prof Julia Newton Bishop, Principal Coordinator of MELGEN received the 2017 Lifetime Achievement Award.Bottom Left: Sabrina Schindler (L) and Marina Juraleviciute (R), received Young Scientist Travel Awards.

Every year since 2009 the SMR have presented a Lifetime Achievement Award to recognise individuals who have made major and impactful contributions to melanoma research throughout their career. The year, this award was presented to Prof Julia Newton Bishop, MELGEN’s Principal Coordinator and Chair of the MELGEN and GenoMEL Consortia. Everyone in MELGEN would like to congratulate her on this fantastic achievement, a testament to her dedicated efforts in furthering knowledge to help melanoma patients both as a clinical dermatologist and melanoma researcher over many years.

The SMR Congress also made awards to two of our MELGEN Early Stage Researchers (ESRs). ESR03, Marina Juraleviciute, and SWISS01, Sabrina Schindler, were both awarded Young Scientist Travel Awards for the 2017 Congress based on the scientific merit of their poster abstracts entitled: ‘Dissecting molecular and genetic determinants of UV response using iPSC based melanocyte models’ and ‘The peripheral blood TCR repertoire might facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma’ respectively. Also receiving a Travel Award was a researcher from MELGEN’s group in Leiden, the Netherlands, based at Leiden University Medical Center (LUMC): Mijke Visser also presented a poster entitled ‘Whole-Genome Sequencing in Dutch Melanoma Families’.

Congratulations to Marina, Sabrina and Mijke on receiving your awards and showing the world the excellent science that the MELGEN Consortium and Early Training Network is producing!